Latest news from the Science Center, our resident companies and the innovation ecosystem.
June 19, 2017 | Resident & Alumni News
Want To Speed Biomedical Research? Do It In Dog Years
Biomedical research takes a long time… Way too long for patients anxiously waiting for treatments that can keep them alive or spare them agony. So, here is an idea. How about switching research’s typical drawn-out, excruciating timeline to dog years. Dog years?
Integral Molecular Announces Technology Advancement for Discovery of New Immuno-Oncology Therapeutic Targets
-Integral Molecular, a leader in membrane protein technologies, has initiated a therapeutic target discovery program in immuno-oncology by exploiting its Membrane Proteome Array technology to identify cell-surface proteins involved in regulating the ability of the human immune system to recognize and destroy cancer.
NextFab officially opens in Wilmington’s Creative District
NextFab, a collaborative makerspace network, officially has a new location in the heart of Wilmington’s Creative District, at 503 Tatnall St. Dozens of members of Delaware’s innovation community celebrated the opening at a Wednesday afternoon event.
Integral Molecular Announces the Expansion of Its Membrane Proteome Array Technology for Improving Antibody Safety and New Target Discovery
Integral Molecular announces the expansion of its proprietary Membrane Proteome Array™ to now consist of 5,300 unique human membrane proteins, representing nearly the entire human membrane proteome, making it the broadest platform of its kind for antibody specificity profiling and de-orphaning.
Enterin’s RASMET study enrolls first patient with Parkinson’s Disease
Enterin, Inc. a CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson’s disease (PD) has enrolled the first patient in the RASMET study. The study is a Phase 1/2a randomized, controlled multi-center study involving patients with PD and taking place at 12 US sites. It will enroll 50 patients over a 9-12 month period. The first Stage is open label and involves single escalating doses in 10 patients with PD. Participating sites include Denver, Boca Raton, Tampa and Cleveland. Details relating to the study can be found at ClinicalTrials.gov. and contact information is available on Enterin’s website, www.enterininc.com.
Intermountain makes strides in precision medicine, advanced imaging
Intermountain HealthCare is making strides on two critical fronts in healthcare: precision genomics and advanced imaging technology. The Salt-Lake City-based health system announced Thursday the Intermountain Precision Genomics service would offer genomic sequencing of solid tumors, a new genomic test for cancer. An adjunct to the ICG100 Comprehensive Cancer panel, which tests 162 genes, the ICG100 ONCO Focus Panel requires less DNA.
Halo Labs announces the launch of a novel low volume, high throughput biopharmaceutical particle analysis system called the Horizon at PEGS 2017 in Boston on May 1st. The new system analyzes sub visible particulate matter in biopharmaceutical samples to enable for the first time rapid particle screening as early as candidate selection and pre-formulation.
Optofluidics today announced that it's changing its corporate name to Halo Labs. The move comes after the company changed focus to making analytical tools for biopharmaceutical quality control. “We are excited about this new market, our new brand and our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson have steered the company in this new direction after identifying significant limitations in current subvisible particle analysis tools.